A National Assessment of Propoxyphene in Postmortem Medicolegal Investigation, 1972–1975

    Volume 21, Issue 4 (October 1976)

    ISSN: 0022-1198

    CODEN: JFSOAD

    Published Online: 1 October 1976

    Page Count: 37


    Finkle, BS
    Director and research toxicologist, Center for Human Toxicology, University of Utah, Salt Lake City, Utah

    Kiplinger, GF
    Vice-president and senior physician, Lilly Research Laboratories, Indianapolis, Ind.

    Bennett, IF
    Vice-president and senior physician, Lilly Research Laboratories, Indianapolis, Ind.

    McCloskey, KL
    Director and research toxicologist, Center for Human Toxicology, University of Utah, Salt Lake City, Utah

    (Received 3 June 1976; accepted 10 June 1976)

    Abstract

    Propoxyphene in its various proprietary forms is among the most commonly prescribed drugs in the United States. As an analgesic which physicians find useful to bridge the gap between aspirin and the narcotics, propoxyphene has reached general application unparalleled by any other “pain-killer.” It is inevitable for any drug with such widespread usage that if it has any toxicity at all, in whatever form or circumstance, it will eventually come to the attention of forensic pathologists and toxicologists. So it has been with propoxyphene in the 1970s through a series of papers in the scientific literature [1–8] suggesting that propoxyphene was increasingly implicated in medicolegal investigations of drug-related deaths. Many groups of cases have been reported by toxicologists in particular areas such as Dallas [3], North Carolina [5], Southern California [1], and the San Francisco Bay area [6], but generally in terms of the analytical toxicology findings alone, and usually as a “snapshot” of an incidence at one point in time.


    Paper ID: JFS10553J

    DOI: 10.1520/JFS10553J

    ASTM International
    is a member of CrossRef.

    Author
    Title A National Assessment of Propoxyphene in Postmortem Medicolegal Investigation, 1972–1975
    Symposium , 0000-00-00
    Committee E30